Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.810 -0.230 (-7.58%)
Streaming Delayed Price Updated: 11:15 AM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease
Via Investor Brand Network
News headline image
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Corporate Update Webinar and Live Q&A Session
Via Investor Brand Network
News headline image
Annovis to Host Corporate Update Webinar on January 28, 2026
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting
Via Investor Brand Network
News headline image
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the CTAD 2025 Conference
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
On Thursday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia ↗
The meeting with the FDA is scheduled for January 2026. 
Via Stocktwits
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program
Via Investor Brand Network
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients ↗
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology. 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports New Data Showing Buntanetap Reverses Cognitive Decline in Parkinson’s Patients With Amyloid Co-Pathology
Via Investor Brand Network
News headline image
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
Topics Intellectual Property
News headline image
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
Via Investor Brand Network
News headline image
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces $3.4 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.